Study of Azacitidine and Durvalumab in Advanced Solid Tumors
PHASE2CompletedINTERVENTIONAL
Enrollment
28
Participants
Timeline
Start Date
September 30, 2016
Primary Completion Date
November 8, 2018
Study Completion Date
August 4, 2020
Conditions
Microsatellite Stable Colorectal CarcinomaPlatinum Resistant Epithelial Ovarian Cancer Type IIEstrogen Receptor Positive and HER2 Negative Breast Cancer
Interventions
DRUG
Azacitidine
DRUG
Durvalumab
Trial Locations (1)
M5G 2M9
Princess Margaret Cancer Centre, Toronto
All Listed Sponsors
lead
University Health Network, Toronto
OTHER
NCT02811497 - Study of Azacitidine and Durvalumab in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter